Activation mechanism dependent surface exposure of cellular factor XIII on activated platelets and platelet microparticles.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
05 2022
Historique:
received: 08 07 2021
accepted: 04 02 2022
pubmed: 12 2 2022
medline: 23 4 2022
entrez: 11 2 2022
Statut: ppublish

Résumé

Platelets contain a high amount of potentially active A subunit dimer of coagulation factor XIII (cellular FXIII; cFXIII). It is of cytoplasmic localization, not secreted, but becomes translocated to the surface of platelets activated by convulxin and thrombin (CVX+Thr). To explore the difference in cFXIII translocation between receptor mediated and non-receptor mediated platelet activation and if translocation can also be detected on platelet-derived microparticles. Our aim was also to shed some light on the mechanism of cFXIII translocation. Gel-filtered platelets were activated by CVX+Thr or Ca Receptor mediated activation by CVX+Thr exposed cFXIII to the surface of more than 60% of platelets. Electron microscopy revealed microparticles with preserved membrane structure and microparticles devoid of labeling for membrane glycoprotein CD41a. cFXIII was observed on both types of microparticles but was more abundant in the absence of CD41a. Rhosin, a RhoA inhibitor, significantly decreased cFXIII translocation. Non-receptor mediated activation of platelets by calcimycin elevated intracellular Ca The elevation of intracellular Ca

Sections du résumé

BACKGROUND
Platelets contain a high amount of potentially active A subunit dimer of coagulation factor XIII (cellular FXIII; cFXIII). It is of cytoplasmic localization, not secreted, but becomes translocated to the surface of platelets activated by convulxin and thrombin (CVX+Thr).
OBJECTIVE
To explore the difference in cFXIII translocation between receptor mediated and non-receptor mediated platelet activation and if translocation can also be detected on platelet-derived microparticles. Our aim was also to shed some light on the mechanism of cFXIII translocation.
METHODS
Gel-filtered platelets were activated by CVX+Thr or Ca
RESULTS
Receptor mediated activation by CVX+Thr exposed cFXIII to the surface of more than 60% of platelets. Electron microscopy revealed microparticles with preserved membrane structure and microparticles devoid of labeling for membrane glycoprotein CD41a. cFXIII was observed on both types of microparticles but was more abundant in the absence of CD41a. Rhosin, a RhoA inhibitor, significantly decreased cFXIII translocation. Non-receptor mediated activation of platelets by calcimycin elevated intracellular Ca
CONCLUSIONS
The elevation of intracellular Ca

Identifiants

pubmed: 35146910
doi: 10.1111/jth.15668
pmc: PMC9303193
pii: S1538-7836(22)00160-X
doi:

Substances chimiques

Carrier Proteins 0
Phosphatidylserines 0
Calcimycin 37H9VM9WZL
Factor XIII 9013-56-3
Thrombin EC 3.4.21.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1223-1235

Subventions

Organisme : British Heart Foundation
ID : PG/07/122/24195
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/11/1/28461
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/11/2/28579
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/20/17/35050
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/82/31721
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

Références

Thromb Res. 2016 May;141 Suppl 2:S17-21
pubmed: 27207415
Thromb Res. 1985 Feb 1;37(3):401-10
pubmed: 2859670
J Thromb Haemost. 2013 Jan;11(1):35-46
pubmed: 23121917
Schweiz Med Wochenschr. 1957 Oct 2;87(39-40):1220-1
pubmed: 13485983
Thromb Diath Haemorrh. 1973 Jun 28;29(3):679-83
pubmed: 4271547
Nature. 2002 Jan 10;415(6868):175-9
pubmed: 11805836
Blood. 2014 Aug 21;124(8):1344-53
pubmed: 24934257
J Immunol Methods. 2001 Dec 1;258(1-2):127-35
pubmed: 11684129
Thromb Haemost. 1995 Apr;73(4):702-5
pubmed: 7495082
Blood. 2016 Feb 4;127(5):626-36
pubmed: 26585954
Int J Mol Sci. 2019 Nov 27;20(23):
pubmed: 31783511
J Thromb Haemost. 2011 Jan;9(1):9-20
pubmed: 20880254
Thromb Haemost. 2001 May;85(5):845-51
pubmed: 11372678
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33802692
Thromb Haemost. 2009 Jul;102(1):83-9
pubmed: 19572072
Biochem J. 1990 Apr 15;267(2):557-60
pubmed: 1970724
Physiol Rev. 2011 Jul;91(3):931-72
pubmed: 21742792
Thromb Haemost. 2017 Jun 2;117(6):1101-1114
pubmed: 28382366
J Biol Chem. 2013 Oct 11;288(41):29621-32
pubmed: 23995838
Front Biosci. 2006 May 01;11:1591-606
pubmed: 16368540
Cell Mol Life Sci. 2018 Oct;75(20):3781-3801
pubmed: 29427073
Thromb Haemost. 1993 Mar 1;69(3):282-5
pubmed: 8097064
Haematologica. 2016 Apr;101(4):427-36
pubmed: 26721892
Blood. 2016 Sep 29;128(13):1745-55
pubmed: 27432876
Eur J Cell Biol. 1985 Jul;38(1):171-3
pubmed: 3896808
Int J Mol Sci. 2021 Jun 19;22(12):
pubmed: 34205443
J Thromb Haemost. 2022 May;20(5):1223-1235
pubmed: 35146910
J Thromb Haemost. 2005 Sep;3(9):2081-8
pubmed: 16102115
Blood. 2014 Dec 18;124(26):3982-90
pubmed: 25331118
Matrix Biol. 2006 Apr;25(3):135-48
pubmed: 16469487
Blood. 2005 Dec 15;106(13):4146-51
pubmed: 16105983
J Thromb Haemost. 2005 Oct;3(10):2185-92
pubmed: 16194197
Thromb Haemost. 2019 Jun;119(6):906-915
pubmed: 30934104
Blood. 2010 Apr 1;115(13):2674-81
pubmed: 20086247
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1499-505
pubmed: 15845904
Blood. 2000 Mar 1;95(5):1694-702
pubmed: 10688826
Pol Tyg Lek (Wars). 1955 Feb 7;10(6):191
pubmed: 14371128
Cell Mol Life Sci. 2003 Jun;60(6):1049-60
pubmed: 12861374
Semin Thromb Hemost. 2016 Jun;42(4):422-8
pubmed: 27019464
Thromb Haemost. 1993 Oct 18;70(4):681-6
pubmed: 8115996

Auteurs

Laura Somodi (L)

Division of Clinical Laboratory Science, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, University of Debrecen, Debrecen, Hungary.

Ildikó Beke Debreceni (I)

Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Gréta Kis (G)

Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Marco Cozzolino (M)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

János Kappelmayer (J)

Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Miklós Antal (M)

Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

György Panyi (G)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Helga Bárdos (H)

Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Nicola J Mutch (NJ)

Aberdeen Cardiovascular and Diabetes Centre, School of Medicine, Medical Science and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

László Muszbek (L)

Division of Clinical Laboratory Science, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH